{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:39:32Z","timestamp":1792132772634,"version":"4.4.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T00:00:00Z","timestamp":1361232000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1038\/nrrheum.2013.8","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T09:52:06Z","timestamp":1361267526000},"page":"154-163","source":"Crossref","is-referenced-by-count":141,"title":["The problem of choice: current biologic agents and future prospects in RA"],"prefix":"10.1038","volume":"9","author":[{"given":"Ernest H.","family":"Choy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur F.","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,19]]},"reference":[{"key":"BFnrrheum20138_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh, J. A.  et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 64, 625\u2013639 (2012).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum20138_CR2","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen, J. S.  et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964\u2013975 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20138_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1590\/S1516-31802010000500013","volume":"128","author":"JA Singh","year":"2010","unstructured":"Singh, J. A.  et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med. J. 128, 309\u2013310 (2010).","journal-title":"Sao Paulo Med. J."},{"key":"BFnrrheum20138_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen, J. S.  et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374, 210\u2013221 (2009).","journal-title":"Lancet"},{"key":"BFnrrheum20138_CR5","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen, S. B.  et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793\u20132806 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR6","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese, M. C.  et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor \u03b1 inhibition. N. Engl. J. Med. 353, 1114\u20131123 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20138_CR7","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery, P.  et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516\u20131523 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20138_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/art.11481","volume":"50","author":"ET Molenaar","year":"2004","unstructured":"Molenaar, E. T.  et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 50, 36\u201342 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR9","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst, D. E.  et al. Adalimumab, a fully human anti tumor necrosis factor-\u03b1 monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30, 2563\u201371 (2003).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum20138_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","volume":"373","author":"L Klareskog","year":"2009","unstructured":"Klareskog, L., Catrina, A. I., Paget, S. Rheumatoid arthritis. Lancet 373, 659\u2013672 (2009).","journal-title":"Lancet"},{"key":"BFnrrheum20138_CR11","doi-asserted-by":"publisher","unstructured":"Isaacs, J. D.  et al. Effect of baseline rheumatoid factor and anti-citrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann. Rheum. Dis. \n                    http:\/\/dx.doi.org\/10.1136\/annrheumdis-2011-201117","DOI":"10.1136\/annrheumdis-2011-201117"},{"key":"BFnrrheum20138_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s11926-011-0201-y","volume":"13","author":"SA Bugatti","year":"2011","unstructured":"Bugatti, S. A.  et al. Synovial tissue heterogeneity and peripheral blood biomarkers. Curr. Rheumatol. Rep. 13, 440\u2013448 (2011).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrrheum20138_CR13","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3899\/jrheum.110426","volume":"38","author":"MJ de Hair","year":"2011","unstructured":"de Hair, M. J.  et al. Synovial tissue analysis for the discovery of diagnostic and prognostic biomarkers in patients with early arthritis. J. Rheumatol. 38, 2068\u20132072 (2011).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum20138_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.2010.139550","volume":"70","author":"MG van de Sande","year":"2011","unstructured":"van de Sande, M. G.  et al. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardization to be used in clinical trials. Ann. Rheum. Dis. 70, 423\u2013427 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20138_CR15","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/ard.2010.134684","volume":"69","author":"IB McInnes","year":"2010","unstructured":"McInnes, I. B. & O'Dell, J. R. State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 69, 1898\u20131906 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20138_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1534\/genetics.110.120907","volume":"187","author":"BE Stranger","year":"2011","unstructured":"Stranger, B. E., Stahl, E. A. & Raj, T. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics 187, 367\u2013383 (2011).","journal-title":"Genetics"},{"key":"BFnrrheum20138_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"M Feldmann","year":"1996","unstructured":"Feldmann, M., Brennan, F. M., Maini, R. N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 14, 397\u2013440 (1996).","journal-title":"Ann. Rev. Immunol."},{"key":"BFnrrheum20138_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/ng.582","volume":"42","author":"EA Stahl","year":"2010","unstructured":"Stahl, E. A.  et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Gen. 42, 508\u2013514 (2010).","journal-title":"Nat. Gen."},{"key":"BFnrrheum20138_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2011.145","volume":"7","author":"RS Woodrick","year":"2011","unstructured":"Woodrick, R. S. & Ruderman, E. M. Safety of biologic therapy in rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 639\u2013652 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum20138_CR20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy, E. H. & Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907\u2013916 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20138_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri2094","volume":"7","author":"IB McInnes","year":"2007","unstructured":"McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429\u2013442 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum20138_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/rheumatology\/kep329","volume":"49","author":"JM Dayer","year":"2010","unstructured":"Dayer, J. M. & Choy, E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 49, 15\u201324 (2010).","journal-title":"Rheumatology"},{"key":"BFnrrheum20138_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","volume":"27","author":"CL Raison","year":"2006","unstructured":"Raison, C. L., Capuron, L. & Miller, A. H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27, 24\u201331 (2006).","journal-title":"Trends Immunol."},{"key":"BFnrrheum20138_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/ard.50.6.395","volume":"50","author":"B Kirkham","year":"1991","unstructured":"Kirkham, B. Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis. Ann. Rheum. Dis. 50, 395\u2013400 (1991).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20138_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s000110050235","volume":"47","author":"G Carroll","year":"1998","unstructured":"Carroll, G., Bell, M., Wang, H., Chapman, H. & Mills, J. Antagonism of the IL-6 cytokine subfamily\u2014a potential strategy for more effective therapy in rheumatoid arthritis. Inflamm. Res. 47, 1\u20137 (1998).","journal-title":"Inflamm. Res."},{"key":"BFnrrheum20138_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/ar2952","volume":"12","author":"N Busso","year":"2010","unstructured":"Busso, N. & So, A. Mechanisms of inflammation in gout. Arthritis Res. Ther. 12, 206 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum20138_CR27","doi-asserted-by":"publisher","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","volume":"7","author":"KJ Aaltonen","year":"2012","unstructured":"Aaltonen, K. J.  et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 7, e30275 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrrheum20138_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3899\/jrheum.100717","volume":"38","author":"JA Singh","year":"2011","unstructured":"Singh, J. A., Beg, S. & Lopez-Olivo, M. A. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 38, 10\u201320 (2011).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum20138_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/rheumatology\/31.5.293","volume":"31","author":"FM Brennan","year":"1992","unstructured":"Brennan, F. M., Maini, R. N. & Feldmann, M. TNF \u03b1--a pivotal role in rheumatoid arthritis? Br. J. Rheumatol. 31, 293\u2013298 (1992).","journal-title":"Br. J. Rheumatol."},{"key":"BFnrrheum20138_CR30","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota, S.  et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 371, 998\u20131006 (2008).","journal-title":"Lancet."},{"key":"BFnrrheum20138_CR31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.coi.2011.08.002","volume":"23","author":"J Silke","year":"2011","unstructured":"Silke, J. The regulation of TNF signalling: what a tangled web we weave. Curr. Opin. Immunol. 23, 620\u2013626 (2011).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrrheum20138_CR32","first-page":"1","volume":"149","author":"D Kamimura","year":"2003","unstructured":"Kamimura, D., Ishihara, K. & Hirano, T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149, 1\u201338 (2003).","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"BFnrrheum20138_CR33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4049\/jimmunol.182.1.613","volume":"182","author":"MA Nowell","year":"2009","unstructured":"Nowell, M. A.  et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol. 182, 613\u2013622 (2009).","journal-title":"J. Immunol."},{"key":"BFnrrheum20138_CR34","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1002\/art.20302","volume":"50","author":"AS de Hooge","year":"2004","unstructured":"de Hooge, A. S.  et al. Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis Rheum. 50, 2014\u20132023 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1101\/gad.183434.111","volume":"26","author":"MS Hayden","year":"2012","unstructured":"Hayden, M. S. & Ghosh, S. NF-\u03baB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 26, 203\u2013234 (2012).","journal-title":"Genes Dev."},{"key":"BFnrrheum20138_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/jir.2010.0100","volume":"31","author":"H Cheon","year":"2011","unstructured":"Cheon, H., Yang, J. & Stark, G. R. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J. Interferon Cytokine Res. 31, 33\u201340 (2011).","journal-title":"J. Interferon Cytokine Res."},{"key":"BFnrrheum20138_CR37","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1172\/JCI57158","volume":"121","author":"SA Jones","year":"2011","unstructured":"Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling. J. Clin. Invest. 121, 3375\u20133383 (2011).","journal-title":"J. Clin. Invest."},{"issue":"Suppl.","key":"BFnrrheum20138_CR38","first-page":"S1034","volume":"63","author":"B Hsu","year":"2011","unstructured":"Hsu, B., Sheng, S., Smolen, J. & Weinblatt, M. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in active rheumatoid arthritis patients despite methotrexate therapy. Arthritis Rheum. 63 (Suppl.), S1034 (2011).","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 3","key":"BFnrrheum20138_CR39","first-page":"471","volume":"70","author":"M Hickling","year":"2011","unstructured":"Hickling, M.  et al. Safety and pharmacokinetics of CDP6038, an anti-IL-6 monoclonal antibody, administered by subcutaneous injection and intravenous infusion to healthy male volunteers: a phase 1 study. Ann. Rheum. Dis. 70 (Suppl. 3), 471 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20138_CR40","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/annrheumdis-2011-200704","volume":"71","author":"P Mease","year":"2012","unstructured":"Mease, P.  et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann. Rheum. Dis. 71, 1183\u20131189 (2012).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 3","key":"BFnrrheum20138_CR41","first-page":"99","volume":"69","author":"A Radin","year":"2010","unstructured":"Radin, A.  et al. Safety and effects on markers of inflammation of subcutaneously administered regn88\/sar153191 (regn88), an interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis: findings from phase 1 studies. Ann. Rheum. Dis. 69 (Suppl. 3), 99 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20138_CR42","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.4049\/jimmunol.1002015","volume":"185","author":"R Lissilaa","year":"2010","unstructured":"Lissilaa, R.  et al. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J. Immunol. 185, 5512\u20135521 (2010).","journal-title":"J. Immunol."},{"key":"BFnrrheum20138_CR43","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/art.21818","volume":"54","author":"PJ Richards","year":"2006","unstructured":"Richards, P. J.  et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum. 54, 1662\u20131672 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1126\/scitranslmed.3001107","volume":"2","author":"W Hueber","year":"2010","unstructured":"Hueber, W.  et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52\u201372 (2010).","journal-title":"Sci. Transl. Med."},{"key":"BFnrrheum20138_CR45","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp, K. A.  et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181\u20131189 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20138_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.sder.2010.02.001","volume":"29","author":"M Gandhi","year":"2010","unstructured":"Gandhi, M.  et al. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin. Cutan. Med. Surg. 29, 48\u201352 (2010).","journal-title":"Semin. Cutan. Med. Surg."},{"key":"BFnrrheum20138_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nri1648","volume":"5","author":"CA Hunter","year":"2005","unstructured":"Hunter, C. A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521\u2013531 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum20138_CR48","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/ni.1899","volume":"11","author":"KM Murphy","year":"2010","unstructured":"Murphy, K. M. & Stockinger, B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol. 11, 674\u2013680 (2010).","journal-title":"Nat Immunol."},{"key":"BFnrrheum20138_CR49","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.immuni.2010.04.016","volume":"32","author":"A Mukasa","year":"2010","unstructured":"Mukasa, A.  et al. Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity 32, 616\u2013627 (2010).","journal-title":"Immunity"},{"key":"BFnrrheum20138_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.immuni.2008.12.009","volume":"30","author":"G Wei","year":"2009","unstructured":"Wei, G.  et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 30, 155\u2013167 (2009).","journal-title":"Immunity"},{"key":"BFnrrheum20138_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.immuni.2008.11.005","volume":"30","author":"KY Lee","year":"2009","unstructured":"Lee, K. Y.  et al. Late developmental plasticity in the T helper 17 lineage. Immunity 30, 92\u2013107 (2009).","journal-title":"Immunity"},{"key":"BFnrrheum20138_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.immuni.2010.01.001","volume":"32","author":"J Zhu","year":"2010","unstructured":"Zhu, J. & Paul, W. E. CD4+ T cell plasticity\u2014TH2 cells join the crowd. Immunity 32, 11\u201313 (2010).","journal-title":"Immunity"},{"key":"BFnrrheum20138_CR53","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.immuni.2009.05.001","volume":"30","author":"L Zhou","year":"2009","unstructured":"Zhou, L.  et al. Plasticity of CD4+ T cell lineage differentiation. Immunity 30, 646\u2013655 (2009).","journal-title":"Immunity"},{"key":"BFnrrheum20138_CR54","doi-asserted-by":"publisher","first-page":"R194","DOI":"10.1186\/ar2893","volume":"11","author":"F Cornelissen","year":"2009","unstructured":"Cornelissen, F.  et al. Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and ROR\u03b3t in \u03b3\u03b4 T cells. Arthritis Res. Ther. 11, R194 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum20138_CR55","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000082102","volume":"8","author":"MS Cragg","year":"2005","unstructured":"Cragg, M. S., Walshe, C. A., Ivanov, A. O. & Glennie, M. J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8, 140\u2013174 (2005).","journal-title":"Curr. Dir. Autoimmun."},{"key":"BFnrrheum20138_CR56","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000082103","volume":"8","author":"JC Edwards","year":"2005","unstructured":"Edwards, J. C., Leandro, M. J. & Cambridge, G. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr. Dir. Autoimmun. 8, 175\u2013192 (2005).","journal-title":"Curr. Dir. Autoimmun."},{"key":"BFnrrheum20138_CR57","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/art.22400","volume":"56","author":"K Vos","year":"2007","unstructured":"Vos, K.  et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 56, 772\u2013778 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR58","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1002\/art.22967","volume":"56","author":"YK Teng","year":"2007","unstructured":"Teng, Y. K.  et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum. 56, 3909\u20133918 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR59","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/art.27359","volume":"62","author":"EM Vital","year":"2010","unstructured":"Vital, E. M.  et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum. 62, 1273\u20131279 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR60","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","volume":"125","author":"T Dorner","year":"2010","unstructured":"Dorner, T., Kinnman, N. & Tak, P. P. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol. Ther. 125, 464\u2013475 (2010).","journal-title":"Pharmacol. Ther."},{"key":"BFnrrheum20138_CR61","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1517\/14712590903018837","volume":"9","author":"F Kausar","year":"2009","unstructured":"Kausar, F.  et al. Ocrelizumab: a step forward in the evolution of B-cell therapy. Exp. Opin. Biol. Ther. 9, 889\u2013895 (2009).","journal-title":"Exp. Opin. Biol. Ther."},{"key":"BFnrrheum20138_CR62","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3109\/10428191003672123","volume":"51","author":"DM Goldenberg","year":"2010","unstructured":"Goldenberg, D. M., Morschhauser, F. & Wegener, W. A. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk. Lymphoma. 51, 747\u2013755 (2010).","journal-title":"Leuk. Lymphoma."},{"key":"BFnrrheum20138_CR63","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1136\/ard.2011.151522","volume":"70","author":"PC Taylor","year":"2011","unstructured":"Taylor, P. C.  et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis. 70, 2119\u20132125 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20138_CR64","first-page":"953","volume":"3","author":"T Dorner","year":"2007","unstructured":"Dorner, T. & Goldenberg, D. M. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther. Clin. Risk Manage. 3, 953\u2013959 (2007).","journal-title":"Ther. Clin. Risk Manage."},{"key":"BFnrrheum20138_CR65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.23178","volume":"58","author":"PP Tak","year":"2008","unstructured":"Tak, P. P.  et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 58, 61\u201372 (2008).","journal-title":"Arthritis Rheum."},{"issue":"Suppl.","key":"BFnrrheum20138_CR66","first-page":"12","volume":"77","author":"SB Cohen","year":"2006","unstructured":"Cohen, S. B. Updates from B cell trials: efficacy. J. Rheumatol. 77 (Suppl.), 12\u201317 (2006).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum20138_CR67","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/art.30372","volume":"63","author":"RF van Vollenhoven","year":"2011","unstructured":"van Vollenhoven, R. F., Kinnman, N., Vincent, E., Wax, S. & Bathon, J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 63, 1782\u20131792 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR68","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/art.30373","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese, M. C., Kinnman, N., de La Bourdonnaye, G., Pena Rossi, C. & Tak, P. P. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 63, 1793\u20131803 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR69","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.1164872","volume":"322","author":"EM Shevach","year":"2008","unstructured":"Shevach, E. M. Immunology: regulating suppression. Science 322, 202\u2013203 (2008).","journal-title":"Science"},{"key":"BFnrrheum20138_CR70","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/0952-7915(93)90132-C","volume":"5","author":"DJ Lenschow","year":"1993","unstructured":"Lenschow, D. J. & Bluestone, J. A. T cell co-stimulation and in vivo tolerance. Curr. Opin. Immunol. 5, 747\u2013752 (1993).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrrheum20138_CR71","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1136\/ard.2008.091876","volume":"68","author":"MH Buch","year":"2009","unstructured":"Buch, M. H.  et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann. Rheum. Dis. 68, 1220\u20131227 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20138_CR72","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jaut.2009.07.006","volume":"34","author":"HJ Ko","year":"2010","unstructured":"Ko, H. J.  et al. CTLA4-Ig modifies dendritic cells from mice with collagen-induced arthritis to increase the CD4+CD25+Foxp3+ regulatory T cell population. J. Autoimmun. 34, 111\u2013120 (2010).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum20138_CR73","first-page":"510","volume":"27","author":"EH Choy","year":"2009","unstructured":"Choy, E. H. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 27, 510\u2013518 (2009).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum20138_CR74","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1002\/art.22139","volume":"54","author":"PH Remans","year":"2006","unstructured":"Remans, P. H.  et al. CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells. Arthritis Rheum. 54, 3135\u20133143 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR75","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s10875-011-9527-5","volume":"31","author":"C Alvarez-Quiroga","year":"2011","unstructured":"Alvarez-Quiroga, C.  et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of TREG cells in patients with rheumatoid arthritis. J. Clin. Immunol. 31, 588\u2013595 (2011).","journal-title":"J. Clin. Immunol."},{"key":"BFnrrheum20138_CR76","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.4049\/jimmunol.1001311","volume":"185","author":"AM Platt","year":"2010","unstructured":"Platt, A. M.  et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J. Immunol. 185, 1558\u20131567 (2010).","journal-title":"J. Immunol."},{"key":"BFnrrheum20138_CR77","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/rheumatology\/41.10.1142","volume":"41","author":"EH Choy","year":"2002","unstructured":"Choy, E. H.  et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) 41, 1142\u20131148 (2002).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum20138_CR78","first-page":"1257","volume":"25","author":"DE Yocum","year":"1998","unstructured":"Yocum, D. E.  et al. Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial. J. Rheumatol. 25, 1257\u20131262 (1998).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum20138_CR79","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/rheumatology\/ken163","volume":"47","author":"JD Isaacs","year":"2008","unstructured":"Isaacs, J. D. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology 47, 1461\u20131468 (2008).","journal-title":"Rheumatology"},{"key":"BFnrrheum20138_CR80","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/01.bor.0000160781.07174.db","volume":"17","author":"JJ O'Shea","year":"2005","unstructured":"O'Shea, J. J., Park, H., Pesu, M., Borie, D. & Changelian, P. New strategies for immunosuppression: interfering with cytokines by targeting the Jak\/Stat pathway. Curr. Opin. Rheumatol. 17, 305\u2013311 (2005).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum20138_CR81","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi, K., Laurence, A. & O'Shea, J. J. Janus kinases in immune cell signaling. Immunol. Rev. 228, 273\u2013287 (2009).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum20138_CR82","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.cell.2009.05.014","volume":"137","author":"H Jiang","year":"2009","unstructured":"Jiang, H.  et al. Cytokine\/Jak\/Stat signaling mediates regeneration and homeostasis in the Drosophila midgut. Cell 137, 1343\u20131355 (2009).","journal-title":"Cell"},{"key":"BFnrrheum20138_CR83","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/BOR.0b013e32835190ef","volume":"24","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann, R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr. Opin. Rheumatol. 24, 335\u2013341 (2012).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum20138_CR84","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","volume":"28","author":"JJ O'Shea","year":"2008","unstructured":"O'Shea, J. J. & Murray, P. J. Cytokine signaling modules in inflammatory responses. Immunity. 28, 477\u2013487 (2008).","journal-title":"Immunity."},{"key":"BFnrrheum20138_CR85","doi-asserted-by":"publisher","unstructured":"Burmester, G. R.  et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet \n                    http:\/\/dx.doi.org\/10.1016\/S0140-6736(12)61424-X\n                    \n                  .","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"BFnrrheum20138_CR86","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bbrc.2011.12.156","volume":"418","author":"H Yoshida","year":"2012","unstructured":"Yoshida, H.  et al. Low dose CP-690, 550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating TH17 differentiation. Biochem. Biophys. Res. Commun. 418, 234\u2013240 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrrheum20138_CR87","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.semarthrit.2005.06.003","volume":"35","author":"CA Sesin","year":"2005","unstructured":"Sesin, C. A. & Bingham, C. O. 3rd. Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin. Arthritis Rheum. 35, 185\u2013196 (2005).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum20138_CR88","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/acr.20188","volume":"62","author":"W Katchamart","year":"2010","unstructured":"Katchamart, W. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res. 62, 1128\u20131143 (2010).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum20138_CR89","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.20221","volume":"50","author":"MC Genovese","year":"2004","unstructured":"Genovese, M. C.  et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50, 1412\u20131419 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20138_CR90","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/ard.2006.055111","volume":"66","author":"M Weinblatt","year":"2007","unstructured":"Weinblatt, M.  et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 66, 228\u2013234 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum20138_CR91","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1002\/art.34497","volume":"64","author":"F D\u00e9pis","year":"2012","unstructured":"D\u00e9pis, F.  et al. Long term amelioration of established collagen-induced arthritis achieved with short term therapy combining anti-CD3 and anti-TNF treatments. Arthritis Rheum. 64, 3189\u20133198 (2012).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:33:47Z","timestamp":1684470827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2013.8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,19]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["BFnrrheum20138"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2013.8","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,19]]}}}